FR2244493A1 - Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis - Google Patents

Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis

Info

Publication number
FR2244493A1
FR2244493A1 FR7329234A FR7329234A FR2244493A1 FR 2244493 A1 FR2244493 A1 FR 2244493A1 FR 7329234 A FR7329234 A FR 7329234A FR 7329234 A FR7329234 A FR 7329234A FR 2244493 A1 FR2244493 A1 FR 2244493A1
Authority
FR
France
Prior art keywords
haemorrhage
atherosclerosis
treatment
acid salts
flavonoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR7329234A
Other languages
English (en)
French (fr)
Other versions
FR2244493B1 (enExample
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PLURIPHARM
Original Assignee
PLURIPHARM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PLURIPHARM filed Critical PLURIPHARM
Priority to FR7329234A priority Critical patent/FR2244493A1/fr
Publication of FR2244493A1 publication Critical patent/FR2244493A1/fr
Application granted granted Critical
Publication of FR2244493B1 publication Critical patent/FR2244493B1/fr
Granted legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/30Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/322,3-Dihydro derivatives, e.g. flavanones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR7329234A 1973-08-09 1973-08-09 Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis Granted FR2244493A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7329234A FR2244493A1 (en) 1973-08-09 1973-08-09 Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7329234A FR2244493A1 (en) 1973-08-09 1973-08-09 Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis

Publications (2)

Publication Number Publication Date
FR2244493A1 true FR2244493A1 (en) 1975-04-18
FR2244493B1 FR2244493B1 (enExample) 1977-09-02

Family

ID=9123835

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7329234A Granted FR2244493A1 (en) 1973-08-09 1973-08-09 Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis

Country Status (1)

Country Link
FR (1) FR2244493A1 (enExample)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031206A3 (en) * 1995-04-07 1996-12-12 Warner Lambert Co Flavones and coumarins as agents for the treatment of atherosclerosis
WO2007016525A3 (en) * 2005-07-29 2007-05-31 Resverlogix Corp Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
CN100412070C (zh) * 2006-07-07 2008-08-20 山东师范大学 槲皮素衍生物及其制备方法与应用
AU2006233256B2 (en) * 2006-10-30 2012-01-19 Armaron Bio Pty Ltd Improved flavonols
US9610251B2 (en) 2011-11-01 2017-04-04 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
US10131640B2 (en) 2009-03-18 2018-11-20 Resverlogix Corp. Anti-inflammatory agents
US10532054B2 (en) 2007-02-01 2020-01-14 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7846915B2 (en) 2004-10-20 2010-12-07 Resverlogix Corporation Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
JP5602728B2 (ja) 2008-06-26 2014-10-08 レスバーロジックス コーポレイション キナゾリノン誘導体の製造方法
EP2382194B1 (en) 2009-01-08 2014-03-12 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
MX2015007921A (es) 2012-12-21 2016-03-03 Zenith Epigenetics Corp Compuestos heterociclicos novedosos como inhibidores de bromodominio.

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996031206A3 (en) * 1995-04-07 1996-12-12 Warner Lambert Co Flavones and coumarins as agents for the treatment of atherosclerosis
WO2007016525A3 (en) * 2005-07-29 2007-05-31 Resverlogix Corp Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
JP2009502970A (ja) * 2005-07-29 2009-01-29 レスバーロジックス コーポレイション 複合疾患の予防および処置のための薬学的組成物および挿入可能な医療用デバイスによるその送達
CN101365446B (zh) * 2005-07-29 2013-05-22 雷斯弗洛吉克斯公司 预防和治疗复杂疾病的药物组合物及其经由可植入医药装置的递送
CN100412070C (zh) * 2006-07-07 2008-08-20 山东师范大学 槲皮素衍生物及其制备方法与应用
AU2006233256B2 (en) * 2006-10-30 2012-01-19 Armaron Bio Pty Ltd Improved flavonols
US10532054B2 (en) 2007-02-01 2020-01-14 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular diseases
US10131640B2 (en) 2009-03-18 2018-11-20 Resverlogix Corp. Anti-inflammatory agents
US10882828B2 (en) 2009-03-18 2021-01-05 Resverlogix Corp. Anti-inflammatory agents
US11407719B2 (en) 2009-03-18 2022-08-09 Resverlogix Corp. Anti-inflammatory agents
US10016426B2 (en) 2011-11-01 2018-07-10 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US9610251B2 (en) 2011-11-01 2017-04-04 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
US10772894B2 (en) 2015-03-13 2020-09-15 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases

Also Published As

Publication number Publication date
FR2244493B1 (enExample) 1977-09-02

Similar Documents

Publication Publication Date Title
FR2244493A1 (en) Flavonoid amino-acid salts - for treatment of haemorrhage, circulatory disorders and atherosclerosis
ES2122472T3 (es) Derivados de eritromicina, su procedimiento de preparacion y su aplicacion como medicamentos.
HUT49600A (en) Process for producing substituted flavonoid deriatives and salts, thereof, as well as pharmaceutical compositions comprising such compounds
KR870002845A (ko) 식욕조절 및 위암억제용 조성물
IE38979L (en) Tetrazolyl - quinoxalinecarboxamide derivatives
EP0159040A3 (en) Pyridine derivatives and production thereof
JPS5257335A (en) Manufacture of novel, pharmacologically active polysacchiaride degrada tion products
ES2083983T3 (es) Sales del acido n5-n10-metilen-5,6,7,8-tetrahidrofolico.
DK638787A (da) Anthracyclinderivater, deres fremstilling og anvendelse
CH541571A (fr) Procédé de préparation de nouvelles isopropyl-2 tétrahydrooxazines-1,3 substituées
IE39049B1 (en) New 1,4-dihydroquinoline derivatives their production and their medicinal use
CS191217B2 (en) Method of producing novel derivatives of 2,5-dihydroxy benzensulphonic acid
FR2244494A1 (en) Amino-acid salts of flavonoid heterosides - for treatment of vascular disorders such as varicose veins, varicose ulcers, oedema and haemorrhage
FR2119882A1 (en) Calcium hypophosphite-ascorbate/carnitine compsn - used as appetite stimulant
FR2288516A2 (fr) Nouveaux bis-(carboxyalcoylene-thio)-1,10 decanes et leurs derives
EP0019000A4 (en) OSTEOPLASTIC PROMOTOR.
FR2142194A5 (en) Allergen-free pollen extracts - stabilized by freeze-drying
ES8602610A1 (es) Procedimiento para la preparacion de sales de carnitina del acido alfa-glucoso-1-fosforico
ES377523A1 (es) Un procedimiento para fabricar una sustancia combinada, compuesta de acido germanico y cisteina.
FR2356652A1 (fr) Nouvelles penicillines et medicaments contenant ces substances
GB1342643A (en) Thioacetanilide derivatives
FR2583756B1 (fr) Procede de preparation des derives de la 2-halo-nicergoline et leurs sels d'addition avec des acides ainsi que des 2-halonicergolines nouvelles, compositions comportant des 2-halonicergolines et procede de preparation
ES2063784T3 (es) Procedimiento para la preparacion de derivados de pirrolizina.
RO96600A2 (ro) Compimat medicamentos tamponat,destinat tratamentului carentelor de zinc
AU1346776A (en) N-heterocyclyl derivatives of 1,4-methano- and 1,4-ethano- 1,4-dihydro- and 1,2,3,4-tetrahydro-naphthyloxy aliphatic alcohols

Legal Events

Date Code Title Description
ST Notification of lapse